Pediatric transplantation: opportunities for pharmacogenomics and genomics.

摘要: Heterogeneity is the rule among pediatric heart transplant recipients. Patients vary in age, size, organ maturity, immune system maturity and underlying disease etiology, which can all influence post-transplant outcomes. Overall, survival of recipients continues to improve goal remains long-term primary graft mitigation complications adverse events. The evolving fields pharmacogenomics genomics have potential revolutionize personalize care recipients, although clinical validation a cohort lacking, many these technologies are becoming more readily available. We discuss genotype-guided dosing immunosuppressant medications other commonly used after transplantation, donor recipient genotype on risk complications, selection therapies treat use next-generation sequencing for noninvasive detection rejection.